Future Plans

At IOLCP we view the changes needs as an inspiration to improve our existing manufacturing operations. In this fast-paced world, there is a definite need to expand operations & capabilities to keep in touch with the dynamic requirements of a widening base of customers. As an established company that has consistently delivered results in the industry & market, we are committed to enhancing the value we offer to our customers & stakeholders in terms of:

• Growth
• Net worth
• Earnings per share

To maintain & sustain our growth, we have consistently adopted and implemented initiatives to expand our operations and ensure fast-paced, sustainable growth.

The production capacity of Ibuprofen, which has been the stronghold of our Pharma operations. IOLCP recently boosted its Ibuprofen plant capacity to 3600 TPA from 1800 TPA and to further expand the capacity to 6000 TPA.

The company has planned for installation of new manufacturing facilities of following PPIs.

• Rabeprazole
• Lansoprazole
• Omeprazole
• Pantoprazole
• Esomeprazole

With annual installed capacity of 360 MT. The commercial production will start by the end of 2008 to 2010.

The major uses of PPI's are:

• Bind to proton pump and prevent it from producing acid in to the stomach.
• Usage in treatment of variety of gastric ailments.
• Rabiprazole is used to treat conditions where the stomach produces too much acid, including ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome.

We invest judiciously in our R&D activities with a futuristic approach to develop new Molecules and APIs that will meet customer's demand. Existing process improvisation & new process development is also a prime area of concern to meet future challenges.